Privacy Notice for Adverse Events, Medical Information Inquiries and Suspected Product Quality Complaints
Product supply updates
Ensuring continuity of supply of medicines for patients is Organon’s highest priority.
This page is intended for use by UK healthcare professionals only. Trademarks appearing on this website are owned, licensed to, promoted or distributed by Organon Pharma (UK) Limited, company number 820771
|FOSAVANCE® 70 mg/2,800 IU tablets|
|INNOVACE® 5 mg Tablets|
|NEOCLARITYN® 0.5 mg/ml oral solution 100ml|
|NEOCLARITYN® 0.5 mg/ml oral solution 150ml|
|Out of Stock|
|Out of Stock|
|Estimated Resupply Date|
At Organon we take the safety of our patients extremely seriously and work with governments and customs authorities around the world to help control the problems caused by counterfeit medicines.
For more information about counterfeit medicines please visit: Mhra.gov.uk
For all medical enquiries about Organon products please contact us.
Modern slavery, Gender Pay Gap, UK Tax Strategy
Up until 2 June 2021, Organon Pharma (UK) Limited was affiliated to Merck & Co., Inc. of Kenilworth, New Jersey, US and its compliance statements in the UK, as it applies to the Modern Slavery Act, its UK Tax Strategy and Gender Pay Gap, was co-reported for 2020 with Merck Sharp & Dohme (UK) Limited. Details of Organon Pharma (UK) Limited’s compliance with these provisions can be found at: www.msd-uk.com
Date of preparation: August 2021. Job code: GB-NON-110187